Tafamidis: a review of its use in familial amyloid polyneuropathy.
Scott LJ.
Drugs · review; journal article · DOI 10.1007/s40265-014-0260-2 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tafamidis. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
15 träffarAn overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.
Obici L, Merlini G.
Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543784.2014.922541[Familial amyloid polyneuropathy: clinicopathological aspects].
Koike H, Sobue G.
Brain Nerve · journal article; english abstract[Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y.
Brain Nerve · journal article; english abstract[Senile systemic amyloidosis].
Yazaki M, Higuchi K.
Brain Nerve · journal article; english abstractRecent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y.
J Clin Pharm Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1111/jcpt.12145Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR.
J Cardiovasc Transl Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1007/s12265-013-9512-xTafamidis (Vyndaqel): a light for FAP patients.
Nencetti S, Rossello A, Orlandini E.
ChemMedChem · journal article · DOI 10.1002/cmdc.201300245Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR.
J Neurol · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s00415-013-7051-7Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, French Network for FAP (CORNAMYL).
Eur J Neurol · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1111/ene.12225Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Merkies IS.
Neurology · letter; comment · DOI 10.1212/01.wnl.0000429338.33391.87Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR.
Neurology · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1212/wnl.0b013e3182661eb1Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R.
Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1121005109Tafamidis for transthyretin amyloidosis.
de Lartigue J.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2012.48.5.1808486Tafamidis.
Said G, Grippon S, Kirkpatrick P.
Nat Rev Drug Discov · news · DOI 10.1038/nrd3675